Cardiomyopathy in patients with chronic hepatitis C virus
Abstract number: 1733_717
Demirdal T., Saglam H., Demirturk N., Asci Z.
Objectives: A high prevalence of cardiomyopathy has been reported in patients with chronic hepatitis C virus (HCV). In this study, we investigated the relationship between cardiomyopathy and HCV infection.
Methods: Sixty subjects were included in the study. These were divided into two groups. In both groups anti-HCV and HCV RNA were detected and ALT levels were measured. Thirty consecutive anti-HCV and HCV RNA positive patients who were admitted to infectious diseases clinic and provided informed consent were evaluated as study group. The other thirty subjects were assumed control group. Healty volunteers who were anti-HCV and hCV RNA negative and whose ALT was normal were included in the control group. Clinical, electrocardiographic and transthorasic echocardiographic evaluations were performed to all subjects. Valve functions and sistolo-diastolic performance were evaluated. The subjects with diastolic disfunction were evaluated cardiomyopathic.
Results: The age of subjects in both groups ranged from 23 to 78 years. In each group, there were 15 man and 15 women. The groups displayed no significant differences for age and sex distribution. Anti-HCV was positive in all subjects in the study group. In this group, average serum alanine transferase (ALT) and HCV-RNA levels were 73.68±46.60 U/L and 1,289,243±2,042,026 copies/mL, respectively. Valve functions and systolic performance of the subjects in both groups were normal. Diastolic disfunction was observed in 18 patients in the study group and in four patients in the control group. The number of subjects with diastolic disfunction in the study group (n = 18) were significantly higher than the control group (n = 4) (p < 0.05).
Conclusion: Diastolic disfunction is the finding of early stage cardiomyopathy. In this study, we observed diastolic disfunction in HCV infected patients. This result reveals that there may be a relationship between HCV infection and cardiomyopathy. However, larger scale studies to investigate this relationship are required for a conclusive result.
|Session name:||European Society of Clinical Microbiology and Infectious Diseases|
|Location:||ICC, Munich, Germany|
|Back to top|